Engineered immune cells take on Hard-to-Treat tumors
NCT ID NCT05396300
First seen Apr 29, 2026 · Last updated Apr 29, 2026
Summary
This early-phase study tests a new treatment called Anti-CEA CAR-T for people with advanced solid tumors (like colorectal or stomach cancer) that have not responded to standard therapies. The treatment uses a patient's own immune cells, modified to target a protein called CEA on cancer cells. The main goals are to check safety, find the best dose, and see if it can control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
First affiliated hospital, Zhejiang University
RECRUITINGHangzhou, Zhejiang, 310006, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.